University of Burgos
University of Burgos (UBU) is the TAT-CF project coordinator. The principal investigator at UBU is Roberto Quesada, professor in the department of Chemistry. The main role of UBU is to synthesize the compounds to be tested in TAT-CF project. Key staff at UBU are pioneers in the field of development and structure-activity relationships analysis of transmembrane anion transporters.
Steinbeis Innovation Ggmbh
SIZ Zellkulturtechnik (Mannheim, Germany) belongs to the Steinbeis gGmbH (Stuttgart, Germany) and is a private research institute. In the frame of the TAT-CF project we develop genetically encoded fluorescent indicators for chloride and bicarbonate using our proprietary IGAMI technology.
Consiglio Nazionale delle Richerche
The Biophysics Institute at Genova is part of the Italian National Research Council (CNR). The group, lead by Oscar Moran, is responsible for the biophysical characterization of the mechanism of the new anionophores, and for the characterization of anion transport in living cells.
Instituto Giannina Gaslini
Istituto Giannina Gaslini (IGG) is one of the partners in the TAT-CF project. Olga Zegarra-Moran and her group, which are part of the Medical Genetics Unit, has long lasting experience in studying cystic fibrosis pathophysiology and pharmacology. The group is responsible for performing the primary screening and participate in the investigation of the biophysical and physiological properties of the new compounds.
Bioneer Pharma (BIONEER A/S), owned by the Technical University of Denmark, is a non-for-profit, R&D based company that delivers services to pharmaceutical and biotechnological companies.
BIONEER A/S will characterize the anionophores developed in TAT-CF project and will assess their transport across cell culture. Further, BIONEER A/S will evaluate efficacy and will carry out studies of ADME-tox, bioavailability, biodistribution and PK profiles of lead compounds as well as develop suitable drug delivery systems.
Biopraxis Research AIE
Biopraxis Research AIE (BIOPRAXIS) was constituted to drive and support all the research and innovation activities for Praxis Pharmaceutical Group.
BIOPRAXIS will participate in compound efficacy studies and in the assessment of their antimicrobial activity. BIOPRAXIS will be also in charge of Structure-activity-relationship (SAR) studies and of the development of the optimal formulation and drug delivery system for the active compounds. Additionally, BIOPRAXIS is the leader of Dissemination and Exploitation activities.
AVIDIN Research, Development & Trading Co. Ltd.
Avidin is the leader of WP4 (Medicinal Chemistry), in which the company coordinates the structure-activity relationship studies and evaluation of the drugability of potential anionophore compounds along with in silico optimization of selected hits, pharmacophore identification, novel synthetic modifications supporting WP1 (Chemistry) to improve the drugability of lead compounds. Our company will also participate in WP5 (Preclinical studies), where Avidin will determine ADME-tox, bioavailability, biodistribution and PK/PD in animal non-GLP studies. In WP6 (Drug delivery and formulation) Avidin will participate in determining the optimal formulation of the lead transporter compounds.
CSIC Agencia Estatal Consejo Superior de Investigaciones Científicas
The Consejo Superior de Investigaciones Científicas (CSIC) is the largest public research organization in Spain, which is distinguished by its multidisciplinary nature, approaching all knowledge areas, from basic research to top-most advanced technological developments.
The CSIC group will be responsible for the ex-vivo and in-vivo preclinical experiments. The group will also in charge of producing the iPS cell line collection from patients with different mutations and genetic backgrounds.